The short answer
Hair cloning is not an approved treatment. Yet the field is no longer one single speculative idea. It now contains at least two distinct development tracks: cultured follicular cells intended to strengthen existing miniaturising follicles, and engineered follicular units intended to create net-new hairs.
The nearer-term track is rejuvenation. HairClone says it is clinically evaluating injections of multiplied follicle cells in Guatemala, and a registered Phase I/IIa study is testing an autologous dermal-papilla-cell product for androgenetic alopecia. These are meaningful translational steps, but neither establishes an approved, repeatable cure.
Why new follicles are harder
A useful hair follicle is a miniature organ. It must form the right cellular architecture, grow in the correct direction, connect with surrounding tissue and continue cycling. Producing a hair shaft in a laboratory or mouse model is therefore not the same as delivering cosmetically reliable human scalp coverage.
OrganTech’s 2026 work identified an additional supporting mesenchymal population in an in-vitro regeneration system. The result illustrates both progress and complexity: successful regeneration may require a carefully orchestrated community of cells rather than one expanded cell type.
Our assessment
We classify the field as early clinical. Human testing of follicular-cell approaches is real, commercial follicle banking already exists, and industrial partnerships are forming. But there is no completed pivotal evidence package for true follicle cloning and no approved product in a major regulated market.
For readers, the most important signals over the next 24 months will be reproducible human hair-count data, durability beyond one full cycle, safety follow-up, manufacturing consistency and publication of trial protocols and results.